New paradigms in drug R&D: A personal perspective

The Author discusses the recent productivity problems in the pharmaceutical industry, in the context of his 30 year career, and the current responses of the industry driven strongly by disaggregation of the historic R&D model, new fluidites of capital access, and the impacts of genomics and globalization. Full details at the Journal of Commercial Biotechnology

Comments are closed.